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EDITORIAL
Evidence that TGF-b should be a therapeutic target in diabetic
nephropathy
Diabetic nephropathy is now the most common cause of
end-stage renal disease in North America and Europe. New
evidence suggests that the majority of diabetic patients,
whether insulin-dependent or not, are developing fibrotic
changes in glomeruli that, if they live long enough, will
manifest as overt nephropathy. It is also clear that the
current therapy, optimal glycemic control combined with
an angiotensin II antagonist and possibly a low protein diet,
can slow, but not prevent the development or progression
of diabetic nephropathy in most patients.
At the molecular level, the pathological features of
fibrosis in the diabetic kidney resemble fibrosis in other
progressive forms of renal disease, as well as in fibrotic
disorders of a variety of other organs and tissues. Indeed,
the most constant molecular feature of pathological tissue
fibrosis leading to organ failure is overexpression of the
cytokine transforming growth factor-b (TGF-b) [1]. These
common molecular features between the kidney and other
tissues suggest the presence of a generic process underlying
fibrotic diseases, rather than unique organ- or tissue-
specific processes. The concept of a common process of
fibrogenesis is good news for the clinician because it implies
that therapies effective in one fibrotic disorder may be
beneficial in a number of other disorders.
TGF-b’s fibrogenic potential is uniquely powerful be-
cause of three simultaneous actions: (1) stimulation of
matrix synthesis, (2) inhibition of matrix degradation, and
(3) modulation of matrix receptor expression to facilitate
cell-matrix interactions. TGF-b initiates its fibrogenic ef-
fects by acting as a transcription factor for several genes
involved in regulating matrix deposition and cell growth,
including a recently discovered gene, whose product may
function as a cell adhesion protein. This gene is big-h3
(TGF-b-induced gene human clone 3). TGF-b has been
shown to induce big-h3 in a number of cultured cell lines,
and big-h3 is overexpressed in human atherosclerotic and
restenotic vascular lesions. In this issue of Kidney Interna-
tional, Gilbert and coworkers provide evidence that big-h3
is expressed in normal kidney and its overexpression in the
diabetic kidney is closely correlated with that of TGF-b and
type IV collagen [2].
The evidence implicating TGF-b overexpression in the
pathogenesis of experimental and human diabetic nephrop-
athy is now overwhelming [reviewed in 3, 4]. In the
pre-cytokine era a number of factors were thought to play
a role in diabetic nephropathy. These factors, including
high levels of glucose, increased glomerular pressure and
flow, mesangial cell stretch, activation of renin-angiotensin
II, hypertension and non-enzymatic glycation of proteins,
have all been shown to induce TGF-b production in the
kidney or in cultured mesangial or tubular cells [4]. Indeed,
as soon as a rat is made diabetic, glomerular expression of
TGF-b is increased along with the glomerular production
and deposition of matrix components and protease inhibi-
tors induced by TGF-b [5]. Treating diabetic rats with
insulin suppresses the renal production and secretion of
TGF-b, but not to normal levels. Thus, as in humans, the
disease process is retarded, but not prevented.
Renal hypertrophy is one of the earliest findings in
experimental and human diabetes. Although called a
growth factor (all growth factors are cytokines but not all
cytokines are growth factors), TGF-b inhibits the cell cycle
in most types of cells, leading to an increase in volume and
DNA and protein content, that is, hypertrophy. Proximal
tubular cells cultured in high glucose show increased pro-
duction of TGF-b and undergo hypertrophy that is blocked
by a neutralizing TGF-b antibody. In two models of
spontaneous-insulin dependent diabetes, the biobreeding
(BB) rat and the nonobese diabetic (NOD) mouse, the
development of renal hypertrophy was closely correlated
with the increased renal expression of TGF-b [4]. Strepto-
zotocin-induced diabetic mice rapidly develop increased
renal expression of TGF-b, collagen and fibronectin, ele-
vated urinary TGF-b and renal hypertrophy. Administra-
tion of a neutralizing TGF-b antibody suppressed renal
TGF-b, collagen and fibronectin production, and reduced
the expected increase in kidney weight by over 50% [6].
TGF-b overexpression is also tightly linked to the devel-
opment of human diabetic nephropathy [5]. The glomeruli
and tubulointerstitium in humans with biopsy-proven dia-
betic nephropathy show very high levels of the three TGF-b
isoforms along with matrix proteins induced by TGF-b such
as fibronectin EDA1 and plasminogen activator inhibi-
tor-1 (PAI-1). In an earlier study in Kidney International,
the levels of TGF-b mRNA were quantitated in diabetic
glomeruli dissected from human biopsies [7]. TGF-b
mRNA levels were found to be elevated early in diabetic
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nephropathy and to correlate with the patients’ HbA1c
levels. These data, along with the evidence showing that
high glucose induced TGF-b production in cultured renal
cells, strongly suggest that poor glycemic control is a key
factor in inducing TGF-b in the diabetic kidney. In a recent
elegant clinical study, Sharma and coworkers showed that
the human diabetic kidney is a factory for producing
TGF-b and releasing it into the circulation [8]. In contrast
to normal kidneys that extract TGF-b from the blood,
diabetic kidneys produce and release TGF-b into the renal
veins, leading to elevated plasma and urinary levels in
diabetic patients.
Another clinically fascinating aspect of TGF-b is the
growing evidence of a complex and rich interaction be-
tween TGF-b and the renin-angiotensin system (RAS) in
which both act at various points to regulate the actions of
the other [reviewed in 9]. Conceptually, TGF-b and RAS
act together in tissue injury as biological “911” molecules to
maintain homeostasis and initiate repair. Indeed, not only
do they engage in cross-talk, but they have broadly over-
lapping properties. For example, angiotensin II is being
evaluated as a topical agent to enhance wound healing, and
infusion of TGF-b into volume depleted rats produced
vasoconstriction and acute renal failure. Indeed, the
TGF-b induced overexpression of big-3h in the diabetic
kidney was not in the glomerulus, but in the vascular
component of the juxtaglomerular apparatus and the pars
recta of proximal tubules.
The interaction of the RAS and TGF-b has important
clinical implications [9, 10]. Angiotensin II blockade re-
duces tissue levels of TGF-b in kidney and heart, and there
is now a consensus that TGF-b is a key mediator of renal
and cardiac fibrosis associated with activation of the RAS.
In experimental and human kidney diseases, the protective
effect of inhibition of the RAS correlates closely with a
partial suppression of TGF-b production [9, 10]. This
suggests that more complete suppression of TGF-b should
be a therapeutic target in order to achieve a greater
anti-fibrotic effect. There is evidence that this might be
accomplished by using higher doses of drugs that block the
RAS or entirely new drug strategies may be needed. In
diverse disease models, suppressing TGF-b with neutraliz-
ing TGF-b antibodies, the proteoglycan decorin or other
novel approaches has been shown to be therapeutic [1].
With the discovery of big-h3 in the kidney, it joins a list of
tissue markers of TGF-b bioactivity including: TGF-b,
PAI-1, fibronectin EDA1, type I collagen and plasma or
possibly urinary levels of TGF-b. One of more of these
TGF-b markers could be used as a therapeutic measure of
TGF-b suppression. The clinical application of a TGF-b
marker along with a direct TGF-b antagonist combined
with blockade of angiotensin II may prove to be synergistic
and offer new hope to patients who suffer from fibrotic
diseases such as diabetic nephropathy.
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